Answers are grounded in this paper and cite their sources.
Background: Group 3 medulloblastoma (G3-MB) carries the worst prognosis, and validated therapeutic targets downstream of MYC remain limited. We investigated PRMT5-associated molecular and clinical features in G3-MB. Methods and Results: We integrated 763 bulk transcriptomes, approximately 25,000 single-nucleus RNA-seq profiles from 12 G3-MB patients, and 144 paired methylation-expression data. PRMT5 was higher in G3-MB than in SHH tumors and was independently associated with poor overall survival in an institutional validation cohort. Its expression was not associated with copy-number gain, but correlated with promoter hypomethylation and MYC/E2F1/SP1 co-expression. Network analysis placed PRMT5 in a MYC-correlated module enriched for ribosome biogenesis. At single-nucleus resolution, PRMT5-positive tumor cells showed elevated MYC and proliferation programs, although these associations were sensitive to detection threshold and library size. PRMT5-high tumors showed expression of genes linked to PRMT5-inhibitor pathways, DNA damage response, and replication stress. An exploratory seven-gene PRMT5-associated continuous score showed prognostic signal in the training and institutional validation cohorts. Conclusions: Integrated analyses associate PRMT5 with MYC-linked ribosome biogenesis and proliferative programs in G3-MB. PRMT5 is a candidate prognostic marker, and the PRMT5-MYC-ribosome association is a testable preclinical hypothesis; functional studies are needed to establish therapeutic relevance.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: